2and4years N/A. non-institutionalised. (Dementia) (Dementia, cognitive impairment no dementia, or poor screening. diagnosis of depression, diagnosis

Transcription

1 British Journal of Clinical Pharmacology DOI: /bcp Erratum In Ruxton et al. (2015) tables 1 and 2 were omitted from the publication. These tables are shown below: Table 1 Included Study Characteristics Study Design Berdot et al. Campbell et al Carriere et al. Coupland et al. Fox et al. Hien et al Hoffmann et al Randomised control trial Lackner et al Randomised control trial Setting/ Data source Accrual period Sample size Anticholinergic exposure Inclusion criteria (Exclusion criteria) Follow-up Bordeaux, Dijon, Montpellier (France); The 3C study AC drug class Aged 65 years, non-institutionalised, living in either cities, registered with electoral roll. 2and4years Indianapolis-Ibadan Dementia Project (IIDP) AC drug class African Americans aged 70 years, enrolled in IIDP between , normal cognitive function at baseline. (Dementia, cognitive impairment no dementia, or poor screening performance at baseline) 3and6years Bordeaux, Dijon, Montpellier (France); The 3C study AC drug class Aged 65 years, non-institutionalised. (Dementia) 2and4years UK QResearch primary care database. General practices Amitriptyline; Mirtazapine; Paroxetine; Trazodone Aged years, medical record diagnosis of depression, diagnosis made at 65 years, diagnosis was recorded between 1/01/ /12/2007, identified using QResearch primary care database. (Temporary residents, previous diagnosis of depression in the 12-month period prior to their index-recorded, prescribed antidepressants in the 12-month period prior to recorded depression diagnosis, diagnosis of schizophrenia, bipolar disorder or other types of psychoses) England and Wales, UK. Medical Research Council Cognitive Function andageingstudy (MRC CFAS) ACB scale Aged 65 years, living in the community and institutions 2years Sydney, Australia. Fracture Risk Epidemiology in the Elderly study Olanzapine; Risperidone 65 years, living in nursing homes and hostels 1month 494 Olanzapine; Risperidone 65 years, living in the community. Minnesota, USA. Nursing homes Oxybutynin Female, Aged 65, Resident for 3 months in long-stay nursing home unit, MMSE score of 5 23, Global Deterioration Scale score 1month (Continues) 2015 The British Pharmacological Society Br J Clin Pharmacol / 80:4 / / 921

2 Table 1 (Continued) Study Design Setting/ Data source Accrual period Sample size Anticholinergic exposure Inclusion criteria (Exclusion criteria) Follow-up of 3 6, urinary incontinence, 1 symptom or sign of urge urinary incontinence; nocturia or nocturnal enuresis >2 times per night; staff observation that incontinence occurs on way to toilet or resident reports urgency; or medical record documentation of detrusor overactivity or urgency, Ability to swallow medication intact, Medication adherence rate 80% during the week before screening. (Terminal illness, bed-bound, non-communicative, delirium, Lewy body dementia, history of 3 UTI s in previous year or current infection, post-void residual urine volume 150 ml, urethral diverticulum, bladder tumor or stone, severe pelvic organ prolapse or vaginitis, genitourinary surgery within past 6 months, hepatic disease, severe cardiovascular disease, myasthenia gravis, spinal cord injury, bowel movement < every 3 days, history of GI obstruction or decreased motility, current drug therapy for urinary incontinence, Current use of acetylcholinesterase inhibitor or bisphosphonate, investigational drug, systemic or ophthalmic cholinomimetic drug, diphenhydramine, or gastrointestinal antispasmodic within 2 weeks before trial). Aberdeen NHS Grampians, Scotland. Geriatric wards ARS scale Aged 60 years, living in the community and institutions. (Opt-out basis). Aberdeen NHS Grampians, Scotland. Geriatric wards DBI (AC) Aged 60 years, living in the community and institutions. (Opt-out basis). 6.5 months Luukkanen et al. Helsinki, Finland AC drug class Aged 70 years. (Coma). 2 years Mangoni et al Amsterdam, Netherlands. Academic Medical Centre ACB scale; ADS; ARS; DBI (AC) Aged years, admitted with hip fracture and scheduled for surgery. (No informed consent, no blood withdrawal for SAA, no SAA before surgery). 1 year Marras et al. Case control Ontario, Canada. Ontario drug benefit database Quetiapine Aged 70 years, Parkinson s disease. (Dispensed any antipsychotic drug in the year prior to entry, prior diagnoses of primary psychiatric disorders requiring treatment with antipsychotics, diagnostic codes for brain tumour or pituitary disorders in the preceding 5 years, receiving palliative care services in the 6 months prior to entry). 1 month Panula et al. Satakunta province, Western Finland AC drug class Aged 65 years, admitted with hip fracture and scheduled for surgery. (Non-residents undergoing hip fracture surgery in study area). 3 years (Continues) 922 / 80:4 / Br J Clin Pharmacol

3 Table 1 (Continued) Study Design Setting/ Data source Accrual period Sample size Anticholinergic exposure Inclusion criteria (Exclusion criteria) Follow-up Thapa et al Tennessee, USA Amitriptyline; Imipramine; Nortriptyline; Paroxetine; Trazodone Aged 65 years, no antidepressant use during the previous 90 days, restricted to new users of either tricyclic or other heterocyclic antidepressants, SSRI s, or trazodone. (Users of multiple types of antidepressants and those for whom the primary reason for starting therapy was somatic e.g. migraine, peripheral neuropathy, or pain). Trifiro et al Case control The Netherlands. Integrated Primary Care Information IPCI database Clozapine; Olanzapine; Quetiapine; Risperidone Aged 65 years, with dementia, at least 1 year recorded in IPIC database during study period Uusvaara et al. Helsinki, Finland. Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study AC drug class Aged years, non-institutionalised, diagnosis of CVD. 3.3 years Whalley et al. NHS Grampian, Scotland. Scottish Mental Survey AC drug class Aged between years, living independently in the community. 15 months to 5 years Abbreviations: ACB: Anticholinergic cognitive burden scale; AC: Anticholinergic; AC drug class: drugs classified as having anticholinergic effects by individual authors; ADS: Anticholinergic drug scale; CVD: Cardiovascular disease; DBI: Drug burden index; GI: gastrointestinal; MMSE: Mini Mental State Examination; NHS: National Health Service; : not applicable; SSRIs: Selective serotonin reuptake inhibitors; SAA: Serum anticholinergic activity; UTIs: Urinary tract infections. Br J Clin Pharmacol / 80:4 / 923

4 Table 2 Results of Individual Studies Study Outcome Number of events (data used in analysis) /no outcome Risk estimate (95% CI) Variables accounted for Berdot et al. Campbell et al Carriere et al. Coupland et al. Falls 2673/3670 *RR 1.19 ( ) *Unadjusted RR produced using no fall against 1 fall as RR presented in study combined no fall 1 fall against 2 falls. Dementia 339/1313 OR 1.43 ( ) Adjusting for age at baseline, gender, education, and baseline CSI-D score. Dementia 221 (177)/6691 HR 1.65 ( ) Adjusted for centre, age, sex, education, BMI, alcohol, tobacco and caffeine intake, mobility, hypercholesterolemia, ApoE ε4, diabetes mellitus, asthma, depression, ischemic diseases, Parkinson s disease and hypertension. Falls / Amitriptyline HR 1.32 ( ) Adjusted for gender, age (5-year bands), year, Mirtazapine HR 1.19 ( ) Paroxetine HR 1.45 ( ) Trazodone HR 1.55 ( ) depression severity, depression before age 65 years, smoking status, Townsend deprivation score, CHD, diabetes, hypertension, stroke, cancer, dementia, epilepsy/seizures, Parkinson s disease, hypothyroidism, obsessive compulsive disorder, statins, NSAIDs, antipsychotics, lithium, aspirin, antihypertensives, anticonvulsants and hypnotics/anxiolytics / Amitriptyline HR 1.10 ( ) Adjusted for gender, age (5-year bands), Mirtazapine HR 1.76 ( ) Paroxetine HR 1.24 ( ) Trazodone HR 1.82 ( ) year, depression severity, depression before age 65 years, smoking status, Townsend deprivation score, CHD, diabetes, hypertension, stroke, cancer, dementia, epilepsy/seizures, Parkinson s disease, hypothyroidism, OCD, statins, NSAIDs, antipsychotics, lithium, aspirin, antihypertensives, anticonvulsants and hypnotics/anxiolytics. Fox et al. 1223/ ACB OR 1.26 ( ) Adjusting for age, sex, baseline MMSE score, education, social class, number of non-ac medications, and number of health conditions. Hien et al Falls 226 (75)/1779 Olanzapine HR 1.74 ( ) Adjusted for other psychotropics in the model, Risperidone HR 1.32 ( ) age, sex, type of residential care facility, length of stay (log), RCS score, Implicit Illness, Severity Scale score, MMSE score, Parkinson s disease, previous falls, and static balance score. One hundred sixty subjects were missing from analysis because of missing data on one or more variables. Hoffmann et al Lackneretal Falls 47/447 No. (%) No adjustments Olanzapine 23 (11.3%) Risperidone 18 (9.2%) Placebo 6 (6.4%) Olanzapine *OR 1.86 ( ) *Unadjusted OR produced using raw numbers. Risperidone *OR 1.48 ( ) Falls 3/47 Oxybutynin *OR 0.44 ( ) *Unadjusted OR produced using raw numbers. 36/326 ARS score HR 1.04 ( ) Adjusted for age, sex, institution, dementia, CCI, number of non-ac drugs, hospital site, Barthel Index category (<50 vs. 50+). 36/326 DBI (AC) HR 1.10 ( ) Adjusted for age, sex, institution, dementia, CCI, number of non-ac drugs, hospital site, Barthel Index category (<50 vs. 50+). (Continues) 924 / 80:4 / Br J Clin Pharmacol

5 Table 2 (Continued) Study Outcome Number of events (datausedinanalysis) /no outcome Risk estimate (95% CI) Variables accounted for Luukkanen et al. 198/227 HR 1.12 ( ) Adjusted for age, CCI, male gender. Mangoni et al Marras et al. Panula et al. 9/62 (3 months) 3months *Adjusted for age, sex, CCI, preadmission cognitive impairment. 18/53 (1 year) *ARS score HR 1.6 ( ) No adjustments for rest of estimates. ADS HR 1.3 ( ) ABS HR 1.1 ( ) DBI (AC) HR 4.5 ( ) 1year ARS scale HR 1.4 ( ) ADS HR 1.2 ( ) ACB HR 1.1 ( ) DBI (AC) HR 3.2 ( ) 5391 (368)/ Quetiapine OR 1.8 ( ) Adjusted for CCI score, dementia, and changes in residence (community to long term care) between entry and index date 229/232 Males: Males: Adjusted for age, cardiovascular disease, 30 days: HR 2.19 ( ) 3 months: HR 2.52 ( ) 6 months: HR 2.22 ( ) chronic lung disease. *Females: no association between anticholinergics 1 year: HR 1.99 ( ) Females: *no data provided and Thapa et al Falls 3524 (2649)/ Amitriptyline Rate ratio 1.9 ( ) Adjusted for age, sex, race, time since admission to the Imipramine Rate ratio 2.2 ( ) Nortriptyline Rate ratio 2.0 ( ) Paroxetine Rate ratio 1.7 ( ) facility and since the index date, BMI, ambulatory status, no. of activities of daily living in which the resident was totally dependent on care providers, incontinence, cognitive impairment, use of physical restraints, previous falls, and use of anticonvulsants, Trazodone Rate ratio 1.2 ( ) antiparkinsonian drugs, benzodiazepines, antipsychotics, and other sedatives. Trifiro et al Uusvaara et al. 407 (232)/4023 Clozapine OR 1.8 ( ) Adjusted for gender and factors changing the risk Olanzapine OR 6.7 ( ) Quetiapine OR no data Risperidone OR 1.7 ( ) estimate for antipsychotic users by more than 5% (Heart failure, COPD, Parkinson(ism), home-bound lifestyle, benzodiazepines and antibiotics). 71/329 HR 1.57 ( ) Adjusted for age, sex, CCI. Whalley et al. Dementia 45/226 HR 0.67 ( ) Adjusted for age, female gender, IQ at age 11, education, history of dementia in a parent or sibling, personal history of treated heart disease, personal history of treated hypertension; exposed to AC drugs (mild-moderate-strong), APOE ε4. Abbreviations: AC: anticholinergic; ACB: anticholinergic cognitive burden scale; ADS: anticholinergic drug scale; APOE: apolipoprotein E; ARS: anticholinergicriskscale;bmi:bodymassindex;cci:charlsoncomorbidityindex;ci:confidence interval; CHD: coronary heart disease; COPD: chronic obstructive pulmonary disease; CSI-D: Communtiy Screening Interview for Dementia score; DBI: drug burden index; HR: hazard ratio; IQ: intelligence quotient; MMSE: Mini-Mental State Examination; NSAIDs: non-steroidal anti-inflammatory drugs; OCD: obsessive compulsive disorder; OR: odds ratio; RCS: Residential Classification Scale; RR: relative risk. Br J Clin Pharmacol / 80:4 / 925

6 We apologize for this error and any confusion it might have caused. REFERENCE 1 Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause in older adults: a systematic review and meta-analysis. Br J Pharmacol 2015; 80: / 80:4 / Br J Clin Pharmacol